AMGN : Summary for Amgen Inc. - Yahoo Finance

U.S. Markets open in 7 hrs 23 mins

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
163.14+2.73 (+1.70%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close160.41
Bid159.49 x 200
Ask164.84 x 300
Day's Range161.91 - 163.60
52 Week Range133.64 - 184.21
Avg. Volume3,806,680
Market Cap120.05B
PE Ratio (TTM)15.93
Earnings DateN/A
Dividend & Yield4.60 (2.84%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire10 hours ago

    Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine

    THOUSAND OAKS, Calif., April 24, 2017 /PRNewswire/ -- Amgen (AMGN) today announced an expanded commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration builds on a global neuroscience collaboration in Alzheimer's disease and migraine established in 2015 between Novartis and Amgen. This expanded collaboration leverages Novartis' strong and established presence in neuroscience to more effectively reach people with migraine.

  • MarketWatch10 hours ago

    Amgen likely aiming to meet, not beat, first-quarter earnings expectations

    The drugmaker could face a mixed quarter, analysts say.

  • Barrons.com11 hours ago

    Biotech: 3 Things to Focus on as Biogen and Amgen Report

    Top holdings Biogen (BIIB) and Amgen (AMGN) have gained 1.95% and 1.56% ahead of earnings results, respectively. Alliance Bernstein analyst Ronny Gal has an Outperform rating on Biogen with a price target of $310, implying an upside of 12% from its recent price of $277. Gal details three things to watch for when Biogen reports tomorrow: MS sales.